<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753948</url>
  </required_header>
  <id_info>
    <org_study_id>B4335-V</org_study_id>
    <nct_id>NCT00753948</nct_id>
  </id_info>
  <brief_title>Exhaled Levels of Nitric Oxide</brief_title>
  <official_title>The Effect of Nitric Oxide on Pulmonary Resistances and Blood Pressure in Persons With Tetraplegia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previously it was observed that individuals with tetraplegia have reduced baseline airway
      caliber and exhibit non-specific airway hyperresponsiveness (AHR). In persons with
      tetraplegia we have suggested that this is due to overriding cholinergic airway tone. In
      asthma, the mechanisms underlying bronchoconstriction and AHR are more closely tied to airway
      inflammation. Whether AHR in tetraplegia is also related to chronic airway inflammation is
      unknown.

      Recently, a non-invasive technique for assessing airway inflammation has been established in
      asthma that involves measurement of nitric oxide (NO) concentrations (FeNO) in expired air.
      FeNO is elevated in asthma likely due to excess NO production by inflammatory cells within
      the airway Measurement of FeNO in persons with tetraplegia would help in assessing the role
      of airway inflammation in this population. This may have therapeutic significance in such
      individuals. NO in the lung is felt to be the principal inhibitory neurotransmitter of the
      non-adrenergic, non-cholinergic (NANC) system. It is thought that inhalation of NO has no
      effect on airway tone in healthy individuals but reduces methacholine responsiveness while
      having weak direct bronchodilatory effect in asthmatics.

      The primary purpose of this study is to determine the levels of exhaled NO (FeNO) in
      individuals with chronic cervical spinal cord injury (SCI), and to compare them with those
      obtained in age and sex matched able-bodied individuals and subjects with stable mild to
      moderate asthma. If the FeNO levels are high and comparable to those found in asthmatic
      subjects, this will imply the role of chronic inflammation in reduced baseline airway caliber
      and non-specific airway hyper-responsiveness (AHR) exhibited by individuals with chronic
      cervical SCI. If the FeNO levels are comparable with those found in able-bodied controls,
      this will support our previous statement that unopposed cholinergic innervation is
      responsible for low baseline airway caliber and AHR in individuals with chronic tetraplegia.
      Further scientific conclusions about NO and its role in control of airway tone, pulmonary
      resistances and blood pressure will be drawn upon intravenous and inhaled administration of
      L-NAME. This compound has been shown promising results for the treatment and prevention of
      orthostatic hypotension in individuals with tetraplegia. Knowing its effects on airways and
      potential of easier mode of delivery (inhalation vs. intravenous) is of utmost importance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study requires a maximum of five study visits in the following order: 1. nebulized normal
      saline, 2. nebulized 1mg/kg of L-NAME (see below), 3. intravenous normal saline, 4.
      intravenous 1 mg/kg L-NAME, 5. intravenous 2 mg/kg L-Name.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exhaled Levels of Nitric Oxide</measure>
    <time_frame>Exhaled NO was reported as the mean of three values within 10% of each other.</time_frame>
    <description>Nitric Oxide was measured applying a real time technique for measurement of Nitric Oxide in Exhaled Breath Condensate. Elevated Nitric Oxide in exhalate is a measure of elevated production of NO in conditions such as underlying inflammation and/or oxidative stress</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung Function as Measured by Plethysmography</measure>
    <time_frame>During study visits, measures are obtained prior to intervention (intravenous or nebulized) and 60, 120 minutes post intervention.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methacholine Challenge</measure>
    <time_frame>During study visits, methacholine challenge will be performed 120 minutes post intervention.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Tetraplegia</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals with chronic tetraplegia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals with diagnosed mild asthma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Neurologically intact, otherwise healthy, age-matched control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Nitro L-arginine-methylester (L-NAME)</intervention_name>
    <description>A non-specific inhibitor of the nitric oxide synthase enzyme.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent.

          2. Age between 18 and 65 years.

          3. Able-bodied individuals, persons with mild asthma or individuals with tetraplegia for
             at least one year of duration.

          4. Able to perform acceptable pulmonary function tests and follow procedures.

        Exclusion Criteria:

          1. coronary artery disease;

          2. active cigarette smokers or previous smokers who stopped &lt;5 years ago;

          3. MI or stroke within 3 months;

          4. moderate to severe reduction in lung function defined as FEV1 &lt; 70 % predicted (except
             in individuals with tetraplegia);

          5. hypertension;

          6. medications known to affect the cardiovascular system;

          7. pregnancy

          8. current use of cholinesterase medication; and

          9. lack of mental capacity to give informed consent Group specific exclusion criteria for

        Asthmatic subjects:

          1. Moderate to severe disease as per spirometric indices;

          2. testing within 48 hours of last administration of long acting inhaled bronchodilator;

          3. testing within 7 days of last administration of glucocorticoids;

          4. testing within &gt; 24 hours since last administration of leukotriene modifiers; and

          5. testing within 8 hours of last administration of a short acting bronchodilator
             medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miroslav Radulovic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Bronx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Bronx</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Radulovic M, Schilero GJ, Wecht JM, La Fountaine M, Rosado-Rivera D, Bauman WA. Exhaled nitric oxide levels are elevated in persons with tetraplegia and comparable to that in mild asthmatics. Lung. 2010 Jun;188(3):259-62. doi: 10.1007/s00408-009-9207-x. Epub 2009 Dec 15.</citation>
    <PMID>20012982</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2008</study_first_submitted>
  <study_first_submitted_qc>September 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2008</study_first_posted>
  <results_first_submitted>September 27, 2013</results_first_submitted>
  <results_first_submitted_qc>July 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 4, 2014</results_first_posted>
  <last_update_submitted>July 2, 2014</last_update_submitted>
  <last_update_submitted_qc>July 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tetraplegia</keyword>
  <keyword>Mild asthma</keyword>
  <keyword>Exhaled Nitric Oxide</keyword>
  <keyword>NOS inhibitor</keyword>
  <keyword>Spinal cord injury</keyword>
  <keyword>Pulmonary Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quadriplegia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from SCI service of James J. Peters VAMC as well as from SCI outpatient clinics. Participants in the asthma group were recruited through medicine clinic at James J. Peters VAMC. Healthy able-bodied controls were recruited from the group of able-bodied controls that has been doing studies with our center in the past.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Chronic Tetraplegia</title>
          <description>Individuals with chronic tetraplegia
N-Nitro L-arginine-methylester (L-NAME) : A non-specific inhibitor of the nitric oxide synthase enzyme.</description>
        </group>
        <group group_id="P2">
          <title>Mild Asthma</title>
          <description>Individuals with diagnosed mild asthma
N-Nitro L-arginine-methylester (L-NAME) : A non-specific inhibitor of the nitric oxide synthase enzyme.</description>
        </group>
        <group group_id="P3">
          <title>Healthy Control</title>
          <description>Neurologically intact, otherwise healthy, age-matched control
N-Nitro L-arginine-methylester (L-NAME) : A non-specific inhibitor of the nitric oxide synthase enzyme.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chronic Tetraplegia</title>
          <description>Individuals with chronic tetraplegia
N-Nitro L-arginine-methylester (L-NAME) : A non-specific inhibitor of the nitric oxide synthase enzyme.</description>
        </group>
        <group group_id="B2">
          <title>Mild Asthma</title>
          <description>Individuals with diagnosed mild asthma
N-Nitro L-arginine-methylester (L-NAME) : A non-specific inhibitor of the nitric oxide synthase enzyme.</description>
        </group>
        <group group_id="B3">
          <title>Healthy Controls</title>
          <description>Neurologically intact, otherwise healthy, age-matched control
N-Nitro L-arginine-methylester (L-NAME) : A non-specific inhibitor of the nitric oxide synthase enzyme.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="10"/>
                    <measurement group_id="B2" value="42" spread="9"/>
                    <measurement group_id="B3" value="37" spread="10"/>
                    <measurement group_id="B4" value="40" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Exhaled Levels of Nitric Oxide</title>
        <description>Nitric Oxide was measured applying a real time technique for measurement of Nitric Oxide in Exhaled Breath Condensate. Elevated Nitric Oxide in exhalate is a measure of elevated production of NO in conditions such as underlying inflammation and/or oxidative stress</description>
        <time_frame>Exhaled NO was reported as the mean of three values within 10% of each other.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Individuals with chronic tetraplegia
N-Nitro L-arginine-methylester (L-NAME) : A non-specific inhibitor of the nitric oxide synthase enzyme.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Individuals with diagnosed mild asthma
N-Nitro L-arginine-methylester (L-NAME) : A non-specific inhibitor of the nitric oxide synthase enzyme.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>Neurologically intact, otherwise healthy, age-matched control
N-Nitro L-arginine-methylester (L-NAME) : A non-specific inhibitor of the nitric oxide synthase enzyme.</description>
          </group>
        </group_list>
        <measure>
          <title>Exhaled Levels of Nitric Oxide</title>
          <description>Nitric Oxide was measured applying a real time technique for measurement of Nitric Oxide in Exhaled Breath Condensate. Elevated Nitric Oxide in exhalate is a measure of elevated production of NO in conditions such as underlying inflammation and/or oxidative stress</description>
          <units>ppb (parts per bilion)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.72" spread="3.9"/>
                    <measurement group_id="O2" value="20.23" spread="4.64"/>
                    <measurement group_id="O3" value="10.37" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function as Measured by Plethysmography</title>
        <time_frame>During study visits, measures are obtained prior to intervention (intravenous or nebulized) and 60, 120 minutes post intervention.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methacholine Challenge</title>
        <time_frame>During study visits, methacholine challenge will be performed 120 minutes post intervention.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>Individuals with chronic tetraplegia
N-Nitro L-arginine-methylester (L-NAME) : A non-specific inhibitor of the nitric oxide synthase enzyme.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>Individuals with diagnosed mild asthma
N-Nitro L-arginine-methylester (L-NAME) : A non-specific inhibitor of the nitric oxide synthase enzyme.</description>
        </group>
        <group group_id="E3">
          <title>Arm 3</title>
          <description>Neurologically intact, otherwise healthy, age-matched control
N-Nitro L-arginine-methylester (L-NAME) : A non-specific inhibitor of the nitric oxide synthase enzyme.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joshua Hobson</name_or_title>
      <organization>James J. Peters VAMC</organization>
      <phone>(718) 584-9000 ext 3129</phone>
      <email>joshua.hobson@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

